CN116445429A - Beta-alanine ligase mutant and application thereof - Google Patents
Beta-alanine ligase mutant and application thereof Download PDFInfo
- Publication number
- CN116445429A CN116445429A CN202310444653.8A CN202310444653A CN116445429A CN 116445429 A CN116445429 A CN 116445429A CN 202310444653 A CN202310444653 A CN 202310444653A CN 116445429 A CN116445429 A CN 116445429A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid residue
- mutation
- mutant
- mutated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-aminopropionic acid Natural products NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 102000003960 Ligases Human genes 0.000 title claims abstract description 32
- 108090000364 Ligases Proteins 0.000 title claims abstract description 32
- 229940000635 beta-alanine Drugs 0.000 title claims abstract description 22
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 32
- 108010087806 Carnosine Proteins 0.000 claims abstract description 32
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229940044199 carnosine Drugs 0.000 claims abstract description 32
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 32
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 26
- 150000001413 amino acids Chemical group 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 24
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 18
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 13
- 229960001340 histamine Drugs 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- 108020000161 polyphosphate kinase Proteins 0.000 claims description 8
- 239000007858 starting material Substances 0.000 claims description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 229920000388 Polyphosphate Polymers 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000001205 polyphosphate Substances 0.000 claims description 2
- 235000011176 polyphosphates Nutrition 0.000 claims description 2
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 15
- 230000003197 catalytic effect Effects 0.000 abstract description 11
- 101710128687 Alanine-anticapsin ligase Proteins 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- 238000006114 decarboxylation reaction Methods 0.000 abstract description 5
- 241000606750 Actinobacillus Species 0.000 abstract description 4
- 238000005265 energy consumption Methods 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 5
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- ANRUJJLGVODXIK-UHFFFAOYSA-N 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CN=CN1 ANRUJJLGVODXIK-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 101000928111 Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-11545) Alcohol dehydrogenase 1 Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000000703 high-speed centrifugation Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150020334 C18L gene Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 241000589496 Meiothermus ruber Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 244000061632 Prinsepia uniflora Species 0.000 description 1
- 102220497201 Protein Wnt-3a_N87Q_mutation Human genes 0.000 description 1
- 102220534796 Protein quaking_L91A_mutation Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 101100502056 Vaccinia virus (strain Copenhagen) F14L gene Proteins 0.000 description 1
- 101100502058 Vaccinia virus (strain Western Reserve) VACWR053 gene Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 102220347073 c.42C>A Human genes 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 102220080161 rs138834119 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention relates to the field of biotechnology, in particular to a beta-alanine ligase mutant and application thereof. The invention provides a ligase mutant, the amino acid sequence of which is shown as SEQ ID NO. 2. According to the invention, by utilizing the characteristic that one L-amino acid ligase in actinobacillus can catalyze and connect beta-alanine with other amino acids, the high catalytic activity production decarboxylation carnosine is finally obtained by mutating the amino acid residues of the catalytic activity pocket and other relevant parts. The method is greatly superior to a chemical synthesis preparation process, and has outstanding advantages in production cost, energy consumption, product quality and green index. Thus, large scale production of this method would be a preferred option for decarboxylation carnosine production.
Description
Technical Field
The invention relates to the field of biotechnology, in particular to a beta-alanine ligase mutant and application thereof.
Background
Beta-alanine is a naturally occurring beta amino acid whose amino group is attached to the beta-carbon of alanine, rather than the more common alpha-carbon. Beta-alanine is commonly used as a motor supplement and endurance aid that enhances motor performance and promotes overall health, while beta-alanine is also a component of many other short peptides such as decarboxylated carnosine. Decarboxylated carnosine (Decarboxy Carnosine) is a biomimetic peptide with antioxidant capacity and anti-aging effects.
The preparation method of decarboxylated carnosine reported on the market at present is mainly a chemical synthesis method.
The traditional chemical synthesis method is a main production process of the dipeptide product at present, and the preparation process is to utilize beta-alanine protected by Boc and histamine protected by Boc for condensation, and finally remove Boc protecting group, or to use chloropropionyl chloride and histamine hydrochloride as raw materials for distributed synthesis preparation. Both schemes need a large amount of organic solvents, have more production steps and do not meet the requirements of green production.
In summary, the preparation of decarboxylated carnosine by chemical synthesis has the problems of long preparation route, large organic solvent consumption, low final yield and poor product quality. The preparation of the dipeptide by exploring and modifying the L-amino acid connection has great competitive advantage and practical application value, and the development of a new and better production process is a relatively realistic requirement for producing the dipeptide product at present.
Disclosure of Invention
In view of the above, the beta-alanine ligase mutant and the application thereof provided by the invention have the advantages of simple preparation route, high yield, good product quality, high green index in production and easy mass production.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a mutant of Uniprot ID B0BTG0 amino acid ligase, wherein mutation sites comprise:
mutation of amino acid residue 13 to threonine; and/or
Mutation of amino acid residue 14 to phenylalanine; and/or
Mutation of amino acid residue 87 to glutamine; and/or
The amino acid residue at position 91 is mutated to alanine; and/or
Mutation of amino acid residue 239 to asparagine; and/or
Amino acid residue 287 is mutated to valine; and/or
The 291 amino acid residue is mutated to tryptophan; and/or
Amino acid residue 317 is mutated to methionine.
In some embodiments of the invention, the mutation sites of the above mutants further comprise:
mutation of amino acid residue 107 to asparagine; and/or
The amino acid residue at position 170 is mutated to cysteine; and/or
Mutation of amino acid residue 192 to proline; and/or
Amino acid residue 243 is mutated to isoleucine.
In some embodiments of the invention, the mutant has:
(1) An amino acid sequence shown as SEQ ID NO. 2; or (b)
(2) An amino acid sequence obtained by substituting, deleting or adding one or more residues to the amino acid sequence shown in (1), and having the same or similar functions as those of (1); or (b)
(3) An amino acid sequence having at least 70% homology with the amino acid sequence as set forth in (1) or (2);
the plurality is 2 to 60.
The invention also provides a nucleic acid molecule encoding the mutant, which has:
(4) A nucleotide sequence shown as SEQ ID NO. 4; or (b)
(5) A nucleotide sequence obtained by substituting, deleting or adding one or more bases to the nucleotide sequence shown in (4), and having the same or similar function as (4); or (b)
(6) A nucleotide sequence having at least 80% homology with the nucleotide sequence as set forth in (4) or (5);
the plurality is 2 to 200.
The invention also provides expression vectors comprising the above nucleic acid molecules, as well as acceptable genetic elements.
The invention also provides a host cell comprising the above nucleic acid molecule or the above expression vector.
The invention also provides a composition comprising the mutant and adenosine triphosphate.
In some embodiments of the invention, the above composition further comprises a polyphosphate kinase and a polyphosphate;
the polyphosphoric acid includes metaphosphoric acid.
In some embodiments of the invention, the polyphosphate kinase in the above composition has:
(7) An amino acid sequence shown as SEQ ID NO. 1; or (b)
(8) An amino acid sequence obtained by substituting, deleting or adding one or more residues to the amino acid sequence shown in (7), and having the same or similar functions as those of (7); or (b)
(9) An amino acid sequence having at least 90% homology with the amino acid sequence as set forth in (7) or (8);
the plurality is 2 to 30.
The invention also provides the use of any of the following in decarboxylation carnosine synthesis:
(i) The mutant;
(ii) The nucleic acid molecules described above;
(iii) The expression vector;
(iv) The host cell;
(v) And the composition.
The invention also provides a preparation method of the decarboxylated carnosine, which comprises the following steps:
(a) Mixing the raw materials with the mutant to obtain the decarboxylated carnosine; ###
(b) Expressing the nucleic acid molecules, and mixing the obtained protein product with raw materials to obtain the decarboxylated carnosine; or (b)
(c) Expressing the expression vector, and mixing the obtained protein product with raw materials to obtain the decarboxylated carnosine; or (b)
(d) Culturing the host cell, and mixing the obtained protein product with a raw material to obtain the decarboxylated carnosine; or (b)
(e) Mixing the raw materials with the composition to obtain the decarboxylated carnosine;
the raw materials include beta-alanine and histamine.
The ligase mutant and the application thereof have the following effects:
according to the invention, by utilizing the characteristic that one L-amino acid ligase in actinobacillus can catalyze and connect beta-alanine and other amino acids, the high catalytic activity production decarboxylation carnosine is finally obtained by mutating the catalytic activity pocket of the L-amino acid ligase and other amino acid residues at relevant positions. The method is greatly superior to a chemical synthesis preparation process, and has outstanding advantages in production cost, energy consumption, product quality and green index. Thus, large scale production of this method would be a preferred option for decarboxylation carnosine production.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below.
FIG. 1 shows an HPLC plot of a Ligase ADH2 reaction for 3 hours;
FIG. 2 shows a nuclear magnetic spectrum of the product decarboxylated carnosine of example 1;
FIG. 3 shows a mass spectrum of the product decarboxylated carnosine in example 1;
FIG. 4 shows an HPLC chromatogram of the modification of wild B0BTG0 to the intermediate mutant B0BTG0-130 enzyme reaction for 3 hours.
Detailed Description
The invention discloses a beta-alanine ligase mutant and application thereof, and a person skilled in the art can refer to the content of the specification to properly improve the technological parameters. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the methods and applications described herein, and in the practice and application of the techniques of this invention, without departing from the spirit or scope of the invention.
The patent discloses a novel and simple scheme for preparing decarboxylated carnosine at low cost and high efficiency by adopting beta-alanine ligase.
Screening results by a large number of amino acid ligase catalytic substrate activities showed that one L-amino acid ligase (Uniprot: B0BTG 0) present in actinobacillus (Actinobacillus pleuropneumoniae) has the ability to ligate beta-alanine with other various amino acids such as beta-alanine, L-cysteine, L-histidine, etc. However, the catalytic activity is still too weak, and the catalytic substrate is too narrow, so that the catalyst cannot be directly applied to industrial production. The enzyme is used as a reconstruction template, rational site-directed mutagenesis and irrational random mutagenesis are combined, finally, the ligase with high catalytic activity on beta-alanine and histamine is screened from 6000 mutant libraries, and the actual catalytic process optimization is combined, so that the amplified production of the decarboxylated carnosine is finally successfully realized.
The amino acid ligase method of the patent comprises the following steps:
this route utilizes inexpensive amino acids without protecting groups as starting materials for high yield conversion to the corresponding dipeptide product under the action of equivalent amounts of Adenosine Triphosphate (ATP) and the corresponding amino acid ligase. In order to further save the cost, the ATP recycling system is introduced into the reaction system, so that the ATP usage amount can be further reduced. Therefore, the preparation method has the advantages of simple preparation route, high yield, good product quality, high green index in production and easy mass production.
The invention can directly connect and convert two target amino acid raw materials into corresponding dipeptide products in one step in buffer solution by using corresponding amino acid ligase. The Adenosine Triphosphate (ATP) required during the reaction may be equivalent or catalytic (by being complexed with an ATP regeneration system, the polyphosphate kinase PPK and metaphosphoric acid are employed).
Enzyme related information:
amino acid Ligase (Ligase ADH 2): the template gene is derived from an L-amino acid ligase (Uniprot: B0BTG 0) existing in the actinobacillus (Actinobacillus pleuropneu moniae) body; and (5) taking the modified material as a template for transformation. Specific mutation site information for Ligase ADH 2: H13T, F14L, N87Q, L91A, K107N, V170C, E192P, P239N, S243I, P287V, T291W, Y317M.
Polyphosphate Kinase (PPK): is derived from Thermus rhodochrous (Meiothermus ruber) (uniprotID: M9XB 82).
The sequence information of the enzymes is shown in tables 1 and 2.
TABLE 1
TABLE 2
Fermentation production of accessory enzyme: the enzyme required by the invention is prepared by constructing a specific expression plasmid after synthesizing corresponding genes by commercial companies and then producing the corresponding genes by escherichia coli fermentation, and specifically comprises the following steps: after sequence optimization, the genes corresponding to the enzymes are ordered to be synthesized by general biological company (Chuzhou of Anhui), and NdeI/XhoI restriction sites are introduced and subcloned into a pET-28a expression vector; plasmid with correct sequence was confirmed to be transferred into E.coli (BL 21) competent cells plate culture (of the species Prinsepia) and monoclonal miniculture, the bacteria with correct protein expression are finally amplified and cultured step by step. Specifically, single colony is transferred into 5ml LB culture solution (37 ℃) containing 50 mu M kanamycin for culture, when cells grow to the logarithmic phase, the cells are inoculated into 250ml LB culture solution containing the same antibiotics, and when the cells grow to the logarithmic phase, the cells are transferred into a 5L culture fermentation tank for culture and final protein expression is carried out. In 5L fermentation tank culture, 0.5mM isopropyl-beta-D-thiopyran galactoside (IPTG) is added at 25 ℃ to induce protein expression for 6 hours when the cells OD-20, and finally the cells are collected by high-speed centrifugation (4000 rpm,20 min) to obtain 25-50 g of wet cells with over-expressed enzyme. A small amount of cells are firstly mixed with a buffer solution (50 mM, pH 8.0) of tris (hydroxymethyl) aminomethane hydrochloride (Tris.HCl) on an ice basin uniformly, then the cells are broken by a freeze thawing method, and clear liquid is subjected to SDS-PAGE gel electrophoresis (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) after cell walls are removed by high-speed centrifugation to determine protein expression. Cells with correct protein expression were used for the next catalytic experiment, specifically, the remaining cells were mixed with Tris.HCl buffer (50 mM, pH 8.0) at low temperature (200 ml buffer mixing with 10 g wet cells), then crushed cell walls at low temperature Gao Yapo, and the cell walls were removed by high speed centrifugation (16000 rpm,45 min) to obtain enzyme-containing supernatant (the enzyme activity obtained was 500-1000U/ml, U was the amount of enzyme required for converting 1. Mu. Mol of substrate in one minute at room temperature). LB medium consisted of: 1% tryptone, 0.5% yeast powder, 1% NaCl,1% dipotassium hydrogen phosphate and 5% glycerol.
The table of the attached enzyme activity statistics is shown in Table 3.
TABLE 3 Table 3
Properties of (C) | Ligase ADH2 | PPK |
Unit vitality | 850~1000U/mg | 950~1400U/mg |
Thermal stability (30 ℃ C.) | T 1/2 =35min | T 1/2 =80min |
Enzyme expression level mg pure protein/liter culture solution | 400~600 | 700~900 |
Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all commercially available and commercially available.
The invention is further illustrated by the following examples:
example 1: preparation of decarboxylated carnosine (Decarboxy Carnosine) Using Ligase (Ligase ADH 2)
To 1L 100mM tris (hydroxymethyl) aminomethane hydrochloride (Tris.HCl) solution at pH 7.5 was added 16.6 g of histamine (150 mM), 16 g of beta-alanine (180 mM), 87.5 g of adenosine triphosphate monosodium salt (ATP, 165 mM), and after the pH of the reaction system was adjusted to 7.5 by NaOH aqueous solution, the reaction was started by adding Ligase Ligase ADH2 2000U, and after stirring slightly at 30℃and maintaining the pH of the reaction system between 6.5 and 8.5, the reaction of histamine starting material was detected to be substantially complete by HPLC after 3 hours, and FIG. 1 shows an HPLC chart. However, the method is thatThen regulating pH to 2.0 with HCl aqueous solution, carrying out enzyme denaturation precipitation in the reaction system, centrifuging to remove protein solids, regulating pH of the reaction solution to 7.0, directly loading the reaction solution into a D201 anion exchange resin purification column, removing adenosine diphosphate and free phosphoric acid impurities, and finally desalting the crude product by using a reverse osmosis membrane, concentrating and crystallizing (ethanol: water, 3:1, v: v) to obtain 24.8 g of decarboxylated carnosine (yield 91%). And (3) confirming that the product is decarboxylated carnosine through sample feeding nuclear magnetism and mass spectrum. The nuclear magnetic resonance spectrum and mass spectrum result are respectively shown in figure 2 fig. 3. 1 H NMR(400MHz,D 2 O)δ8.66(s,1H),7.34(s,1H),3.56(t,J=6.5Hz,2H),3.28(t,J=6.5Hz,2H),3.00(t,J=6.5Hz,2H),2.70(t,J=6.5Hz,2H).ESI+:[m+H] + :183.1;[2m+H] + :365.3。
Example 2: preparation of decarboxylated carnosine (Decarboxy Carnosine) Using Ligase (Ligase ADH 2) and an ATP regenerating System
To 1L 100mM tris (hydroxymethyl) aminomethane hydrochloride (Tris.HCl) solution at pH 7.5 was added 16.6 g histamine (150 mM), 16 g beta-alanine (180 mM), 2.7 g adenosine triphosphate monosodium salt (ATP, 5 mM), 33.6 g sodium metaphosphate (55 mM), after adjusting the pH of the solution to 7.5, 3000U of polyphosphate kinase PPK enzyme was added, and the reaction was started by adding Ligase Ligase ADH2 2000U, slightly stirred at 30℃and maintained at pH of the reaction system between 6.5 and 8.5, after 3 hours the reaction of the histamine starting material was detected to be substantially complete by HPLC. Then regulating pH to 2.0 by using an HCl aqueous solution, carrying out enzyme denaturation precipitation in a reaction system, centrifuging to remove protein solids, regulating the pH of the reaction solution to 7.0, directly loading the reaction solution into a D201 anion exchange resin purification column, removing adenosine diphosphate and free phosphoric acid impurities, and finally desalting a crude product by using a reverse osmosis membrane, concentrating and crystallizing (ethanol: water, 3:1, v: v) to obtain 25.9 g of decarboxylated carnosine (yield 95%).
Comparative example: preparation of decarboxylated carnosine (Decarboxy Carnosine) Using wild-type ligase (B0 BTG 0), wild-type ligase mutant (B0 BTG 0-130)
Control group 1:
to 1L 100mM tris (hydroxymethyl) aminomethane hydrochloride (Tris.HCl) solution at pH 7.5 was added 16.6 g of histamine (150 mM), 16 g of beta-alanine (180 mM), 87.5 g of adenosine triphosphate monosodium salt (ATP, 165 mM), and after the pH of the reaction system was brought to 7.5 by NaOH aqueous solution, the reaction was started by adding wild type ligase B0BTG0 2000U, and after stirring slightly at 30℃and maintaining the pH of the reaction system between 6.5 and 8.5, 60% of histamine starting material was still left by HPLC after 3 hours, and the reaction was very incomplete.
Control group 2:
to 1L 100mM tris (hydroxymethyl) aminomethane hydrochloride (Tris.HCl) solution at pH 7.5 was added 16.6 g of histamine (150 mM), 16 g of beta-alanine (180 mM), 87.5 g of adenosine triphosphate monosodium salt (ATP, 165 mM), and after the pH of the reaction system was brought to 7.5 by NaOH aqueous solution, the reaction was started by adding wild type ligase B0BTG0-130 2000U, and after stirring slightly at 30℃and maintaining the pH of the reaction system between 6.5 and 8.5, 30% of histamine starting material was still left by HPLC after 3 hours, which was shown in FIG. 4.
Table 4: comparison summary of mutant B0BTG0-130 and the mutant of the invention
The mutant Ligase ADH2 and the mutant B0BTG0-130 are compared, and the conversion rate is improved by 21%.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (10)
- A mutant of an amino acid ligase having a uniprot ID of B0BTG0, characterized in that the mutation site comprises:mutation of amino acid residue 13 to threonine; and/orMutation of amino acid residue 14 to phenylalanine; and/orMutation of amino acid residue 87 to glutamine; and/orThe amino acid residue at position 91 is mutated to alanine; and/orMutation of amino acid residue 239 to asparagine; and/orAmino acid residue 287 is mutated to valine; and/orThe 291 amino acid residue is mutated to tryptophan; and/orAmino acid residue 317 is mutated to methionine.
- 2. The mutant of claim 1, wherein the mutation site further comprises:mutation of amino acid residue 107 to asparagine; and/orThe amino acid residue at position 170 is mutated to cysteine; and/orMutation of amino acid residue 192 to proline; and/orAmino acid residue 243 is mutated to isoleucine.
- 3. The mutant according to claim 2, which has:(1) An amino acid sequence shown as SEQ ID NO. 2; or (b)(2) An amino acid sequence obtained by substituting, deleting or adding one or more residues to the amino acid sequence shown in (1), and having the same or similar functions as those of (1); or (b)(3) An amino acid sequence having at least 70% homology with the amino acid sequence as set forth in (1) or (2);the plurality is 2 to 60.
- 4. A nucleic acid molecule encoding the mutant according to claim 2 or 3, which has:(4) A nucleotide sequence shown as SEQ ID NO. 4; or (b)(5) A nucleotide sequence obtained by substituting, deleting or adding one or more bases to the nucleotide sequence shown in (4), and having the same or similar function as (4); or (b)(6) A nucleotide sequence having at least 80% homology with the nucleotide sequence as set forth in (4) or (5);the plurality is 2 to 200.
- 5. An expression vector comprising the nucleic acid molecule of claim 4, and an acceptable genetic element.
- 6. A host cell comprising the nucleic acid molecule of claim 4 or the expression vector of claim 5.
- 7. A composition comprising a mutant according to any one of claims 1 to 3 and adenosine triphosphate.
- 8. The composition of claim 7, further comprising a polyphosphate kinase and a polyphosphate;the polyphosphoric acid includes metaphosphoric acid.
- 9. Use in the synthesis of decarboxylated carnosine of any of the following:(i) A mutant according to any one of claims 1 to 3;(ii) The nucleic acid molecule of claim 4;(iii) The expression vector of claim 5;(iv) The host cell of claim 6;(v) A composition according to claim 7 or 8.
- 10. A method for preparing decarboxylated carnosine, comprising:(a) Mixing a raw material with the mutant according to any one of claims 1 to 3 to obtain the decarboxylated carnosine; or (b)(b) Expressing the nucleic acid molecule of claim 4, mixing the obtained protein product with a starting material to obtain said decarboxylated carnosine; or (b)(c) Expressing the expression vector according to claim 5, mixing the obtained protein product with a raw material to obtain the decarboxylated carnosine; or (b)(d) Culturing the host cell of claim 6, mixing the obtained protein product with a starting material to obtain the decarboxylated carnosine; or (b)(e) Mixing the raw materials with the composition according to claim 7 or 8 to obtain the decarboxylated carnosine;the raw materials include beta-alanine and histamine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310444653.8A CN116445429A (en) | 2023-04-14 | 2023-04-14 | Beta-alanine ligase mutant and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310444653.8A CN116445429A (en) | 2023-04-14 | 2023-04-14 | Beta-alanine ligase mutant and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116445429A true CN116445429A (en) | 2023-07-18 |
Family
ID=87120046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310444653.8A Pending CN116445429A (en) | 2023-04-14 | 2023-04-14 | Beta-alanine ligase mutant and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116445429A (en) |
-
2023
- 2023-04-14 CN CN202310444653.8A patent/CN116445429A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111172129B (en) | Phi29DNA polymerase mutant for improving thermal stability, amplification uniformity and amplification efficiency and application thereof | |
CN111172142B (en) | Cephalosporin C acylase mutant with high thermal stability | |
CN116410938B (en) | Beta-alanine ligase mutant and application thereof | |
CN111808829B (en) | Gamma-glutamyl methylamine synthetase mutant and application thereof | |
CN112522228B (en) | R-aminotransferase from pseudomonas ammoxidation and synthesis method thereof | |
CN112251428B (en) | Glutamic acid decarboxylase mutant and application thereof in production of gamma-aminobutyric acid | |
CN116855471B (en) | Purine nucleoside phosphorylase mutant and application thereof | |
CN116240187B (en) | Prolyl hydroxylase alpha 1 subunit mutant, coding gene and application thereof in catalyzing hydroxylation of proline | |
CN113088501B (en) | Glutamic acid dehydrogenase mutant for producing L-glufosinate-ammonium and L-glufosinate-ammonium production method | |
CN115992103A (en) | Enzyme mutant and preparation method of snake venom tripeptide | |
CN115806946A (en) | Preparation method of kyotorphin and derivatives thereof | |
CN111133105B (en) | D-amino acid dehydrogenase | |
CN115109770B (en) | Benzaldehyde lyase mutant and application thereof in preparation of 1, 4-dihydroxyl-2-butanone | |
CN114736884B (en) | Cytidine monophosphate kinase mutant and gene and application thereof | |
CN116676280A (en) | Glutathione bifunctional synthetase mutant and application thereof | |
CN116445429A (en) | Beta-alanine ligase mutant and application thereof | |
CN114990080B (en) | Lysine mutant thermostable nucleic acid ligase | |
CN116376853A (en) | Beta-alanine ligase mutant and application thereof | |
CN116426499B (en) | Methyltransferase mutant, biological material and application | |
CN115820575A (en) | Histidine ligase mutant and application thereof | |
CN117511889B (en) | Enzyme and application thereof in preparation of unnatural amino acid dipeptide | |
CN114196642B (en) | Glutamate dehydrogenase variants and their use in the preparation of L-amino acids | |
CN108624574B (en) | S-adenosyl homocysteine hydrolase mutant and application and preparation method thereof, nucleic acid, expression vector and host cell | |
CN115820574A (en) | Leucine ligase mutant and application thereof | |
CN110452899B (en) | Glucose isomerase, mutant and application of mutant in preparation of D-fructose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |